---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-025828"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:57:39.906480+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine

## Summary
- Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.
- Net loss $34.0M ($0.86 per share) vs $25.8M ($0.86) in 2023; R&D expense $41.7M.
- Phase 2 SHIMMER DLB study: up to 91% slowing vs placebo across behavior, cognition, function, movement.
- Phase 2 SHINE Alzheimer's subgroup with lower p-tau217 showed near-total preservation of cognition.
- Plans to request end-of-Phase 2 FDA meetings in Q2 2025 for DLB and Alzheimer's; cash runway into Q4 2025.

## SEC filing metadata
- accession: 0001104659-25-025828
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/0001104659-25-025828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/tm259712d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-025828
- JSON: https://secwatch.observer/filing/0001104659-25-025828.json
- Plain text: https://secwatch.observer/filing/0001104659-25-025828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.